Conjunctival Goblet Cell NLRP3 Inflammasome in Ocular Surface Bacterial Infection

眼表细菌感染中的结膜杯状细胞NLRP3炎症小体

基本信息

  • 批准号:
    8461558
  • 负责人:
  • 金额:
    $ 41.47万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-05-01 至 2016-04-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Bacterial conjunctivitis and keratitis occur in approximately 25,000 Americans annually with Staphylococcus aureus (S. aureus) being the leading cause of infection. If untreated, corneal infections in particular can be sight threatening In addition, the emergence of methicillin-resistant S. aureus makes development of new approaches to control ocular surface infections an immediate goal. Corneal response to infection is constrained, but conjunctiva can respond exuberantly. In particular the MUC5AC-secreting conjunctival goblet cells are the first line of innate immune defense of the ocular surface with their secreted mucin (MUC5AC) trapping and removing the bacteria. It is not known, however, if bacteria interact with goblet cells. The long-term object of this project is to determine: a) if bacteria interact directly with conjunctival goblet cells, b) what cellular signalng mechanisms and functions are triggered in the goblet cells, c) if activation of these functions prevents bacterial keratitis and conjunctivitis, and d) if drugs that activate these functions can e developed to treat ocular surface infections. An innovative hypothesis is that bacteria interact with conjunctival goblet cells and stimulate two distinct responses. First, goblet cells secrete mucin to trap and remove bacteria. Second, goblet cells activate the newly discovered Nod-like receptor (NLRP) 3 an intracellular responder to bacteria. Activation of NLRP3 causes formation of a multi-component complex, the inflammasome that result in the secretion of mature IL-1b that initiates innate mediated inflammation. A second component of this hypothesis is that pathogenic, but not commensal, bacteria interact differently with the goblet cells so that goblet cells mount an immune response against pathogenic, but not commensal, bacteria. The following specific aims will be investigated: 1) Does interaction with goblet cells by pathogenic toxin-forming S. aureus, but not by commensal, non-toxigenic S. epidermidis, cause a protective response by stimulating goblet cell mucin secretion and are the secretory responses distinct because the two types of bacteria activate diverse Toll-like receptor (TLR) dimers (TLR2/1 versus TLR2/6) and different signaling pathways ([Ca2+]/extracellular regulated-kinase (ERK)1/2 versus phosphatidylinositol-3 kinase (PI-3K).AKT)? and 2) Does interaction of pathogenic S. aureus, but not of commensal S. epidermidis, activate the goblet cell NLRP3 inflammasome to produce mature IL-1b and is the mechanism activated: a) channel formation or b) production of reactive oxygen species (ROS),? Cultured rat and human conjunctival goblet cells will be incubated with bacteria or lipoproteins that are pathogen-associated molecular patterns (PAMPs). Intracellular [Ca2+] will be measured by fluorescence microscopy, ERK1/2 by western blotting, and mucin secretion by biochemical assay. NLRP3 formation will be investigated by immunoprecipitation and western blotting, NLRP3 activation by FLICA assay, and secretion of mature IL-1b by ELISA. Agonists, antagonists, chemical inhibitors, and siRNA will be used to characterize responses.
描述(由申请人提供):每年约有25,000名美国人发生细菌性结膜炎和角膜炎,金黄色葡萄球菌(S. aureus)是感染的主要原因。如果不及时治疗,尤其是角膜感染会对视力造成威胁。此外,耐甲氧西林金黄色葡萄球菌的出现使得开发控制眼表感染的新方法成为当务之急。角膜对感染的反应是受限的,但结膜反应旺盛。特别是分泌MUC5AC的结膜杯状细胞是眼表先天免疫防御的第一道防线,它们分泌的粘蛋白(MUC5AC)可以捕获和清除细菌。然而,尚不清楚细菌是否与杯状细胞相互作用。该项目的长期目标是确定:a)细菌是否直接与结膜杯状细胞相互作用;b)杯状细胞中触发了哪些细胞信号机制和功能;c)这些功能的激活是否可以预防细菌性角膜炎和结膜炎;d)是否可以开发出激活这些功能的药物来治疗眼表感染。一个创新的假设是,细菌与结膜杯状细胞相互作用,并刺激两种不同的反应。首先,杯状细胞分泌黏液来捕获和清除细菌。其次,杯状细胞激活新发现的nod样受体(NLRP) 3,这是细胞内对细菌的反应。NLRP3的激活导致多组分复合物的形成,炎症小体导致成熟IL-1b的分泌,引发先天介导的炎症。该假说的第二个组成部分是致病细菌而非共生细菌与杯状细胞的相互作用不同,因此杯状细胞对致病细菌而非共生细菌产生免疫反应。将调查以下具体目标:1)致病性产毒金黄色葡萄球菌与杯状细胞相互作用,而非共生的非产毒性表皮葡萄球菌与杯状细胞相互作用,是否通过刺激杯状细胞粘蛋白分泌而引起保护反应?分泌反应是否不同,因为两种细菌激活不同的toll样受体(TLR)二聚体(TLR2/1 vs TLR2/6)和不同的信号通路([Ca2+]/细胞外调节激酶(ERK)1/2 vs磷脂酰肌醇-3激酶(PI-3K).AKT)?2)致病金黄色葡萄球菌而非共生表皮葡萄球菌的相互作用是否激活杯状细胞NLRP3炎性体产生成熟的IL-1b,其激活机制是a)通道形成还是b)活性氧(ROS)的产生?培养的大鼠和人结膜杯状细胞将与病原体相关分子模式(PAMPs)的细菌或脂蛋白一起培养。细胞内[Ca2+]将通过荧光显微镜测量,ERK1/2通过western blotting,粘蛋白分泌通过生化测定。NLRP3的形成将通过免疫沉淀和western blotting进行研究,NLRP3的激活将通过FLICA试验进行研究,成熟IL-1b的分泌将通过ELISA进行研究。激动剂、拮抗剂、化学抑制剂和siRNA将用于描述反应。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Darlene A Dartt其他文献

Darlene A Dartt的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Darlene A Dartt', 18)}}的其他基金

Mechanisms underlying mustard gas-induced conjunctival injury and use of lipid mediators as medical countermeasures
芥子气引起的结膜损伤的机制以及脂质介质作为医疗对策的使用
  • 批准号:
    10882060
  • 财政年份:
    2023
  • 资助金额:
    $ 41.47万
  • 项目类别:
Construction of Conjunctival Equivalents Using Molecular Deposition Techniques
使用分子沉积技术构建结膜等效物
  • 批准号:
    10338062
  • 财政年份:
    2020
  • 资助金额:
    $ 41.47万
  • 项目类别:
Construction of Conjunctival Equivalents Using Molecular Deposition Techniques
使用分子沉积技术构建结膜等效物
  • 批准号:
    10557095
  • 财政年份:
    2020
  • 资助金额:
    $ 41.47万
  • 项目类别:
Construction of Conjunctival Equivalents Using Molecular Deposition Techniques
使用分子沉积技术构建结膜等效物
  • 批准号:
    9884619
  • 财政年份:
    2020
  • 资助金额:
    $ 41.47万
  • 项目类别:
Construction of Conjunctival Equivalents Using Molecular Deposition Techniques
使用分子沉积技术构建结膜等效物
  • 批准号:
    10089447
  • 财政年份:
    2020
  • 资助金额:
    $ 41.47万
  • 项目类别:
Conjunctival Goblet Cell Mucin Secretion in Inflammation and Its Resolution
炎症中结膜杯状细胞粘蛋白的分泌及其解决
  • 批准号:
    9920424
  • 财政年份:
    2019
  • 资助金额:
    $ 41.47万
  • 项目类别:
Conjunctival Goblet Cell NLRP3 Inflammasome in Ocular Surface Bacterial Infection
眼表细菌感染中的结膜杯状细胞NLRP3炎症小体
  • 批准号:
    8274619
  • 财政年份:
    2012
  • 资助金额:
    $ 41.47万
  • 项目类别:
Conjunctival Goblet Cell NLRP3 Inflammasome in Ocular Surface Bacterial Infection
眼表细菌感染中的结膜杯状细胞NLRP3炎症小体
  • 批准号:
    8663916
  • 财政年份:
    2012
  • 资助金额:
    $ 41.47万
  • 项目类别:
Lacrimal Gland Regeneration:Identification and Isolation of Progenitor Cells
泪腺再生:祖细胞的鉴定和分离
  • 批准号:
    7978066
  • 财政年份:
    2010
  • 资助金额:
    $ 41.47万
  • 项目类别:
Conjunctival Goblet Cell Mucin Secretion in Inflammation and Its Resolution
炎症中结膜杯状细胞粘蛋白的分泌及其解决
  • 批准号:
    8990960
  • 财政年份:
    2009
  • 资助金额:
    $ 41.47万
  • 项目类别:

相似国自然基金

Agonist-GPR119-Gs复合物的结构生物学研究
  • 批准号:
    32000851
  • 批准年份:
    2020
  • 资助金额:
    24.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
  • 批准号:
    24K12256
  • 财政年份:
    2024
  • 资助金额:
    $ 41.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
  • 批准号:
    24K19176
  • 财政年份:
    2024
  • 资助金额:
    $ 41.47万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
  • 批准号:
    10578068
  • 财政年份:
    2023
  • 资助金额:
    $ 41.47万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 41.47万
  • 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
  • 批准号:
    10650593
  • 财政年份:
    2023
  • 资助金额:
    $ 41.47万
  • 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
  • 批准号:
    10649275
  • 财政年份:
    2023
  • 资助金额:
    $ 41.47万
  • 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
  • 批准号:
    10784209
  • 财政年份:
    2023
  • 资助金额:
    $ 41.47万
  • 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
  • 批准号:
    10734158
  • 财政年份:
    2023
  • 资助金额:
    $ 41.47万
  • 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
  • 批准号:
    10580259
  • 财政年份:
    2023
  • 资助金额:
    $ 41.47万
  • 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
  • 批准号:
    23K05057
  • 财政年份:
    2023
  • 资助金额:
    $ 41.47万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了